835882-04-7Relevant articles and documents
DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS
-
Page/Page column 65-66, (2014/10/15)
The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors
Wall, Mark J.,Chen, Jinsheng,Meegalla, Sanath,Ballentine, Shelley K.,Wilson, Kenneth J.,DesJarlais, Renee L.,Schubert, Carsten,Chaikin, Margery A.,Crysler, Carl,Petrounia, Ioanna P.,Donatelli, Robert R.,Yurkow, Edward J.,Boczon, Lisa,Mazzulla, Marie,Player, Mark R.,Patch, Raymond J.,Manthey, Carl L.,Molloy, Christopher,Tomczuk, Bruce,Illig, Carl R.
, p. 2097 - 2102 (2008/12/21)
A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4-yl)-2-qui
